Clinical trials: Active Population
HIV Infections
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients…
- Trial name
- NCT00561925
- Testing
- nevirapine IR, nevirapine XR
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 1,068 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Other Acute Postoperative Pain
Study of Diclofenac Capsules to Treat Pain Following Bunionectomy
The purpose of this study is to determine whether Diclofenac [Test] Capsules are safe and effective for the treatment of bunionectomy pain.
- Trial name
- NCT01462435
- Testing
- Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib
- Where
- 4 sites in United States
- Volunteers
- 428 people
- Sponsor
- Iroko Pharmaceuticals, LLC
GHD
A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency
The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.
- Trial name
- ELEVATE (NCT06007417)
- Testing
- GenSci004, Genotropin
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular…
- Trial name
- NCT00753168
- Testing
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Othera Pharmaceuticals
Schizophrenia
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms of schizophrenia in adult schizophrenia patients.
- Trial name
- NCT00921804
- Testing
- AZD 8529, Risperidone
- Where
- 3 sites in United States
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Osteoarthritis, Knee, Pain
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
- Trial name
- NCT01688934
- Testing
- V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules
- Where
- 18 sites in United States
- Volunteers
- 230 people
- Sponsor
- Purdue Pharma LP
Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
This study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for…
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects
- Trial name
- NCT06751121
- Testing
- DWP14012 40mg, DWC202301 30mg, Amoxicillin 1000mg
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetic Macular Edema (DME)
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
- Trial name
- NCT04739306
- Testing
- CT-P42, Eylea
- Where
- Slovakia
- Volunteers
- 348 people
- Sponsor
- Celltrion
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Crohn's Disease
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
- Trial name
- NCT00584740
- Testing
- AIN457
- Where
- 2 sites in Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Anaemia
A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
This study is to evaluate the efficacy and safety of QLG1218(daprodustat) following a switch from erythropoiesis-stimulating agent (ESA) in Chinese HD subjects with renal anemia who are currently treated with ESA.
- Trial name
- NCT07300111
- Testing
- Daprodustat, Darbepoetin alfa
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atrophic Vaginitis Due to Menopause
Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo
The purpose of this study is to compare the safety and efficacy of generic Estradiol Vaginal Inserts, USP 10 mcg to the reference product Vagifem® 10 mcg and to determined whether the efficacy of each of the 2 active treatments…
- Trial name
- NCT01779947
- Testing
- Estradiol Vaginal Tablets 10 mcg
- Where
- 25 sites in United States
- Volunteers
- 519 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Type 2 Diabetes Mellitus
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with…
- Trial name
- NCT00859898
- Testing
- Dapagliflozin, Metformin XR
- Where
- 123 sites in United States, India and 4 more
- Volunteers
- 1,093 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
This study was designed to assess the efficacy and long-term safety of 300 and 600 µg doses of indacaterol when delivered via a single-dose dry-powder inhaler (SDDPI) in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00393458
- Testing
- Indacaterol, Formoterol
- Where
- 183 sites in Argentina, Chile and 23 more
- Volunteers
- 1,732 people
- Sponsor
- Novartis
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Essential Hypertension
Essential Hypertension
The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.
- Trial name
- REDUCE-1 (NCT01264692)
- Testing
- ACT-280778, Amlodipine
- Where
- 18 sites in Israel, Serbia
- Volunteers
- 196 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.